GLP-1
Clinical Guide

Additional access model

Blue Sky MD Review

What is the full program cost, and which prescription and visit arrangement does it cover?

Published offer / checked October 15, 2026

GLP-1 page lists $40/week semaglutide and $60/week tirzepatide, but a table says monthly; required program cost needs a quote.

Blue Sky MD combines a North Carolina medical weight-loss program with medication when a clinician considers it appropriate. Its public offer is not a stand-alone low-price injection service: the GLP-1 page requires enrollment in the wider program. That requirement matters when interpreting the advertised medication price. [Source]

We checked the program, GLP-1, virtual-visit and privacy pages on October 15, 2026. This review records their terms and unresolved questions; we did not enroll, verify insurance benefits, test shipping or examine patient records. It is not a clinical endorsement or an independent audit of the practice’s results.

01 / Establish the practice and available visit format

The medical weight-loss page identifies founder David LaMond, MD, and a team of physicians, nurse practitioners, dietitians and wellness coaches. It lists seven North Carolina locations, including Asheville, Hendersonville, Greensboro, Winston-Salem and three in the Charlotte/Lake Norman area. The website privacy policy identifies parent company LaMond Family Medicine, PLLC. These are the practice’s published identities; we did not independently verify individual licenses or this reader’s clinician assignment. [Source]

Virtual visits are advertised, but the online page retains blood draws and necessary in-person medical appointments. Its broad geographic wording does not establish nationwide prescribing. Confirm whether your location is eligible, which appointments must occur in person and whether virtual coaching is distinct from a prescribing visit. [Source]

02 / Resolve the weekly-versus-monthly price conflict

At the top of the GLP-1 page, in-office semaglutide is advertised at $40 per week and tirzepatide at $60 per week. A comparison table farther down the same page calls those figures monthly prices. We cannot reconcile that discrepancy from the public offer and do not present the lower monthly interpretation as confirmed. [Source]

Enrollment in the medical weight-loss program is required for medication. Its full self-pay cost is not stated in the reviewed pages. A medication headline therefore does not establish the total charge for visits, coaching, tests, supplies or delivery. Ask for the actual billing period and a written total covering both the program and the proposed prescription. [Source]

The practice says it accepts many insurance plans and can help check benefits, while an older virtual-visit page broadly claims coverage by all carriers. Neither statement verifies coverage for your plan, the selected service or the medicine. Separate the practice’s network status, laboratory benefits and prescription coverage; a free online assessment is not a promise that medical care is free.

03 / Distinguish branded products from compounded offers

The GLP-1 page lists Wegovy, Ozempic, Zepbound and Mounjaro alongside its ingredient-level prices. Its FAQ also refers to medication compounded by the practice. Those descriptions do not identify the exact preparation or dispensing pharmacy supplied at a given price. Ask whether the proposed product is a branded approved medicine or a compounded preparation, and obtain the responsible pharmacy’s details. [Source]

Compounded preparations are not FDA-approved. A branded medicine’s evidence and approved uses do not automatically apply to every preparation containing the same ingredient. FDA’s concerns about unapproved GLP-1 products are relevant context for reviewing any proposed compounded prescription. [Source]

04 / Read outcome and microdosing claims with their limits

Blue Sky MD advertises roughly 13% average weight loss over twelve weeks and a comparison with medication alone. It describes a study of 559 practice patients, while another page refers to a 2025 study of more than 500 patients. We did not obtain a full study report establishing its methods, comparator, follow-up or adverse-event findings. The marketing summary does not establish that this program will outperform a branded medicine for a particular patient. [Source]

The site also markets an individualized microdosing approach with claims about tolerability, muscle preservation and long-term metabolic health. We have not verified comparative evidence for that specific protocol. This review does not recommend a dose or treat the marketing claims as an established benefit. Ask the treating professional to explain the proposed plan, evidence and product-specific instructions.

05 / Put testing, follow-up and exit terms in writing

The program describes laboratory assessment, metabolic evaluation and continuing coaching. Ask what each proposed test is intended to answer, who interprets it, what would change the plan and which services are optional. Separate any proposed hormone treatment from the decision about a weight-loss medicine; a combined service menu is not evidence that every treatment is needed. [Source]

The GLP-1 page advertises prescription delivery within three to five business days after approval. That is a company fulfillment claim, not a tested delivery or support guarantee. Public pages reviewed here do not establish a complete cancellation cutoff, renewal schedule, no-show fee or unused-program refund policy. Request the patient financial agreement before payment. [Source]

Our test-purpose briefing offers questions for that conversation. The AFC Urgent Care review shows a different clinic model with local prepaid terms. Compare the full care arrangement, not just the smallest medication number.

Our assessment: Blue Sky MD describes a structured clinical program with in-person and virtual elements, but the price-period conflict, required program cost, exact preparation and exit terms remain material questions. We have not independently validated its certification, patient-review totals or clinical outcomes, and assign no clinical quality score.

Source notes

New provider sources checked October 15, 2026. Earlier material retains its original source history. Provider pages document advertised terms. Study summaries identify the scope of our review.

  1. Blue Sky MD: GLP-1 prices, required program and outcome claimsProvider public information; checked October 15, 2026
  2. Blue Sky MD: Medical weight-loss program and insuranceProvider public information; checked October 15, 2026
  3. Blue Sky MD: Online visits and in-person requirementsProvider public information; checked October 15, 2026
  4. Blue Sky MD: Website operator and privacy policyProvider public information; checked October 15, 2026
  5. FDA: Concerns with unapproved GLP-1 drugs used for weight lossMedication safety context; checked October 15, 2026

Return to the access comparison →